Comparative Evaluation of Sacubitril/Valsartan and Apelin‑13 in Experimentally Induced Cardiac Disease in Rats
DOI:
https://doi.org/10.63939/t68h2348Keywords:
Sacubitril/Valsartan, Apelin‑13, Cardiac Diseases, RatsAbstract
Background: In the world, cardiovascular diseases are the best morbidity and mortality causes. Objective: The proposed research is a comparative study of the therapeutic implications of Sacubitril/Valsartan (SAC/VAL) and Apelin-13 on the therapeutic effects of the effects of cardiac diseases induced experimentally in rats. Methods: Wistar rats were randomly selected as males and divided into three groups; control, SAC /VAL -treated, and Apelin-13 -treated. The physiological parameters, serum biochemical markers, inflammatory markers, and heart-specific biomarkers were used to evaluate the cardiac functioning. The data were given in the form of mean +- SD and tested via one-way ANOVA. Results: The findings indicated that SAC/VAL had significant cardiac parameter improvements over Apelin-13 and control groups, whereas Apelin-13 had moderate cardioprotective improvements. Conclusion: SAC/VAL demonstrates better cardioprotective properties than Apelin13 in rats with induced cardiac disease, has a better lipid profile, lowering myocardial injury, and decreasing inflammation. Protective effects are also provided by Apelin-13 but could be most effectively implemented as a form of adjunctive therapy. These results allow speculating on possible treatment plans of cardiac dysfunction.
Downloads
References
1. Liu W, Yan J, Pan W, Tang M. Apelin/Elabela‑APJ: a novel therapeutic target in the cardiovascular system. Annals of Translational Medicine, 2020;8(5):243. doi:10.21037/atm.2020.02.07.
2. Mustafa NH, Jalil J, Zainalabidin S, Saleh MS, Asmadi AY, Kamisah Y. Molecular mechanisms of sacubitril/valsartan in cardiac remodeling. BMC Cardiovascular Disorders, 2022; 22:734. doi:10.1186/s12872‑022‑02981‑x.
3. Liu Y, Sun Y, Dai W. Effect of sacubitril–valsartan on left ventricular remodeling: a meta‑analysis. Frontiers in Pharmacology, 2024; 15:1366035. doi:10.3389/fphar.2024.1366035.
4. Tantisuwat L, Saengklub N, Boonpala P, Kumphune S, Panyasing Y, Kalandakanond‑Thongsong S & Kijtawornrat A. Sacubitril/valsartan mitigates cardiac remodeling, systolic dysfunction, and preserves mitochondrial quality in a rat model. Scientific Reports, 2023;13:11472. doi:10.1038/s41598‑023‑38694‑6.
5. Zeng GG, et al. Apelin‑13: A protective role in vascular diseases. Pharmacological Research, 2024; 188:106700. doi:10.1016/j.phrs.2024.106700.
6. Helmi HR, Sunjaya AP, Limanan D, Prijanti AR, Jusman SWA, Suyatna FD. Apelin‑13/APJ and BNP‑45 gene expression in a rat heart failure model. European Heart Journal, 2019;40 (Suppl 1). doi:10.1093/eurheartj/ehz745.0354.
7. Moraña-Fernández S, Vázquez-Abuín X, Aragón-Herrera A, et al., Cardiometabolic effects of sacubitril/valsartan in a rat model of heart failure with preserved ejection fraction. Biochem Pharmacol., 2024; 230:116571. doi:10.1016/j.bcp.2024.116571.
8. Zeng GG, Tang SS, Jiang WL, Yu J, Nie GY, Tang CK. Apelin-13: A protective role in vascular diseases. Curr Probl Cardiol., 2024;49(1 Pt B):102088. doi:10.1016/j.cpcardiol.2023.102088.
9. Salvail W, Salvail D, Chagnon F, Lesur O. Apelin-13 administration allows for norepinephrine sparing in a rat model of cecal ligation and puncture-induced septic shock. Intensive Care Med Exp., 2024; 12:68. doi:10.1186/s40635-024-00650-7
10. Erdoğan BR, Yesilyurt-Dirican ZE, Karaomerlioglu I, Muderrisoglu AE, Sevim K, Michel MC, Arioglu-Inan E. Sacubitril/valsartan combination partially improves cardiac systolic, but not diastolic, function through β-AR responsiveness in a rat model of type 2 diabetes. Int J Mol Sci., 2024;25(19):10617. doi:10.3390/ijms251910617.
11. Maroof NT, Mehrzadi S, Naseroleslami M, Aboutaleb N. Apelin13-loaded nano-niosomes confer cardioprotection in a rat model of myocardial ischemia–reperfusion by targeting the Nrf2/HO-1 pathway. J Cardiovasc Transl Res., 2025;18(3):529–543. doi:10.1007/s12265-025-10597-z.
12. Nägele, M. P., Haider, T., Kreysing, L., Barthelmes, J., Nebunu, D., Rossi, V. A., Hebeisen, M., Sudano, I., Ruschitzka, F., & Flammer, A. J. (2024). Vascular endothelial effects of sacubitril/valsartan in heart failure with reduced ejection fraction: A randomized controlled trial. JACC: Advances, 3(12), 101392. https://doi.org/10.1016/j.jacadv.2024.101392.
13. Jeremic, J., Govoruskina, N., Bradic, J., Milosavljevic, I., Srejovic, I., Zivkovic, V., … Filipovic, N. (2023). Sacubitril/valsartan reverses cardiac structure and function in an experimental model of hypertension-induced hypertrophic cardiomyopathy. Molecular and Cellular Biochemistry, 478(12), 2645–2656. https://doi.org/10.1007/s11010-023-04690-7
14. Shi YJ, Yang CG, Qiao WB, Liu YC, Liu SY, Dong GJ. Sacubitril/valsartan attenuates myocardial inflammation, hypertrophy, and fibrosis in rats with heart failure with preserved ejection fraction. Eur J Pharmacol., 2023; 961:176170. doi:10.1016/j.ejphar.
15. Gan J, Wang Y, Deng Y, Zhang J, Wang S, Jiang X, Guo M, Song L. Sacubitril/valsartan ameliorates cardiac function and ventricular remodeling in CHF rats via the inhibition of tryptophan/kynurenine metabolism and inflammation. Sci Rep., 2024; 14:12377. doi:10.1038/s41598-024-62472-7.
16. Zeng XJ, Zhang LK, Wang HX, Lu LQ, Ma LQ. Apelin-13 protects the heart against ischemia/reperfusion injury in rats. Peptides, 2010;30(6):1144–1152. doi:10.1016/j.peptides.
17. Zhang X, Hu W, Feng F, Xu J, Wu F. Apelin‑13 protects against myocardial infarction‑induced myocardial fibrosis. Molecular Medicine Reports, 2016 Jun;13(6):5262‑5268. doi:10.3892/mmr.2016.5163.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 International Journal of Environmental and Biological Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
